10-K: United Therapeutics Reports Strong 2024 Results, Driven by Tyvaso DPI Growth

United Therapeutics' 2024 annual report highlights significant revenue growth, particularly driven by Tyvaso DPI, and advancements in manufactured organs and organ alternatives.

Summary

• United Therapeutics' 2024 revenues increased by 24% to $2.88 billion, driven by strong performance of Tyvaso DPI and overall growth in Tyvaso sales.
• Tyvaso DPI and nebulized Tyvaso combined net product sales reached $1.62 billion, representing 56% of total revenues.
• Remodulin sales increased by 9% to $538.1 million, while Orenitram sales grew by 21% to $434.3 million.
• Unituxin sales increased by 20% to $238.7 million, while Adcirca sales decreased by 18% to $23.8 million.
• The company is actively pursuing research and development projects, including phase 3 studies for nebulized Tyvaso in IPF and PPF, and the ADVANCE OUTCOMES study for ralinepag in PAH.
• United Therapeutics is also focused on developing manufactured organs and organ alternatives, including xenotransplantation, regenerative medicine, and 3D bioprinting technologies.
• The company's human capital management prioritizes challenging work, career advancement, autonomy, inspiring environment, and competitive pay and benefits.
• United Therapeutics is constructing additional facilities to support the development and commercialization of its products and technologies, with a focus on Tyvaso DPI and xenotransplantation.
• The company faces competition from established drug companies and new therapies, including generic versions of its products and innovative treatments from competitors like Merck and Liquidia.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and advancements in key areas, but also acknowledges potential risks and challenges, resulting in a moderately optimistic sentiment.

Positives

• Significant revenue growth driven by Tyvaso DPI and overall Tyvaso sales.
• Advancements in research and development of manufactured organs and organ alternatives.
• Low employee turnover rate, indicating a positive work environment.
• FDA clearance to commence a clinical trial for UKidney, a xenotransplantation product.
• Positive feedback from the MHRA regarding nebulized Tyvaso for PH-ILD, potentially leading to marketing authorization in the UK.

Negatives

• Adcirca sales decreased by 18% due to generic competition.
• Potential competition from Liquidia's Yutrepia, which could receive final FDA approval in May 2025.
• Ongoing litigation with Sandoz and Liquidia, which could result in significant costs and adverse outcomes.
• Dependence on a limited number of distributors for a significant portion of revenues.
• Potential impact of the Inflation Reduction Act (IRA) on prices and reimbursement rates.

Risks

• Competition from established drug companies and new therapies.
• Potential generic competition for nebulized Tyvaso and Orenitram in the future.
• Manufacturing and supply chain disruptions.
• Failure of clinical trials or delays in obtaining regulatory approvals.
• Cybersecurity incidents and data security threats.
• Dependence on third parties for manufacturing and distribution.
• Potential product liability claims and recalls.
• Changes in laws and regulations affecting the healthcare industry.
• Inability to attract and retain key management and qualified scientific and technical personnel.

Future Outlook

United Therapeutics anticipates continued revenue growth driven by Tyvaso DPI, PH-ILD treatments, and Orenitram, with potential for further growth from pipeline products and new indications. The company is also focused on developing manufactured organs and organ alternatives.

Industry Context

The announcement reflects the competitive landscape of the cardiopulmonary disease and cancer treatment market, with United Therapeutics competing against established pharmaceutical companies and facing potential competition from generic versions of its products and innovative therapies from competitors.

Comparison to Industry Standards

• Johnson & Johnson reported global sales of Uptravi of nearly $1.6 billion in 2023, including over $1.3 billion in U.S. sales, reflecting a growth rate of approximately 20 percent over 2022.
• The implied net present value of future Tyvaso DPI net revenues at the time of the transaction between MannKind and Sagard Healthcare Funding Partners Borrowers 2 SPE, LP was $15.0 billion.
• United Therapeutics achieved approximately $2.2 million in revenue per employee in 2024, which ranks near the top of its industry peer group.
• United Therapeutics' voluntary turnover at 4.6 percent, well below industry average of 11.0 percent (based on June 1, 2023 through June 1, 2024 data from Aons Turnover Study for the Life Sciences/Biotech/Pharma Sector , published December 2024).

Legal Proceedings

• The company is engaged in litigation with Liquidia concerning a patent covering the treatment of PH-ILD to improve exercise capacity in patients suffering from PH-ILD by inhaling treprostinil at specific dosages.
• Liquidia sued the FDA, challenging the grant of regulatory exclusivity to Tyvaso DPI through May 2025, and United Therapeutics intervened in this lawsuit.
• The company is engaged in litigation with Sandoz related to the infusion devices used to administer Remodulin subcutaneously.
• Humana and United Healthcare filed lawsuits against United Therapeutics alleging violations of RICO and various state laws in connection with donations to a charity.

Stakeholder Impact

• Shareholders: The company seeks to provide shareholders with superior financial performance.
• Patients: The company's public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
• Communities: The company seeks to provide communities with earth-sensitive energy utilization.
• Employees: The company is committed to providing employees with challenging work, career advancement opportunities, autonomy, an inspiring work environment, and competitive pay and benefits.

Next Steps

• Continue enrollment in the ADVANCE OUTCOMES study, targeting completion in mid-2025 and accruing clinical worsening events through the end of 2025.
• Seek FDA approval to expand the nebulized Tyvaso label to include IPF and PPF if the TETON studies are successful.
• Seek FDA approval to expand the Tyvaso DPI label to include IPF and PPF, following completion of any FDA-required bridging studies.
• Submit an MAA to the MHRA in 2025 for nebulized Tyvaso to treat PH-ILD.
• Launch RemunityPRO later this year.
• Close enrollment in mid-2025 and accrue clinical worsening events through the end of 2025 for the ADVANCE OUTCOMES study.
• Confirm essential facility design criteria with the FDA for a commercial-scale DPF facility.

Key Dates